by Lori Solomon The U.S. Food and Drug Administration has approved an additional indication for AstraZeneca’s Fasenra (benralizumab) as an add-on maintenance treatment for patients aged 6 to 11 years with severe asthma and an eosinophilic phenotype. This indication was supported by evidence from the Phase III TATE trial, as well as data from additional...
